Benjamin Ortiz
Overview
Explore the profile of Benjamin Ortiz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
724
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maspero J, Bachert C, Martinez F, Hanania N, Ortiz B, Patel N, et al.
J Asthma Allergy
. 2023 Apr;
16:333-342.
PMID: 37026112
Purpose: To provide a descriptive summary of clinical efficacy and health-related quality of life (HRQoL) measures in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and clinical features of obstructive...
2.
Brusselle G, Quirce S, Papi A, Kuna P, Chipps B, Hanania N, et al.
J Allergy Clin Immunol Pract
. 2022 Dec;
11(3):873-884.e11.
PMID: 36572184
Background: Type 2 cytokines IL-4/IL-5/IL-13 play an important role in pathogenesis of type 2 conditions, including asthma. Dupilumab, a human monoclonal antibody, blocks the shared receptor component for IL-4/IL-13, inhibiting...
3.
Pavord I, Deniz Y, Corren J, Casale T, FitzGerald J, Izuhara K, et al.
J Allergy Clin Immunol Pract
. 2022 Dec;
11(4):1213-1220.e2.
PMID: 36535524
Background: FeNO may have a role as both a prognostic and predictive biomarker in combination with eosinophils for assessing responsiveness to some biological therapies. Objective: We evaluated the value of...
4.
Tohda Y, Nakamura Y, Fujisawa T, Ebisawa M, Msihid J, Djandji M, et al.
Allergol Int
. 2022 Sep;
72(1):89-99.
PMID: 36114102
Background: Safety and efficacy data for dupilumab beyond 1 year are lacking for patients from Japan with moderate-to-severe asthma. Methods: The TRAVERSE open-label extension (OLE) study (NCT02134028) assessed the safety...
5.
Bourdin A, Virchow J, Papi A, Lugogo N, Bardin P, Antila M, et al.
Respir Med
. 2022 Sep;
202:106938.
PMID: 36087550
Background And Objective: Dupilumab blocks the shared receptor component for interleukin (IL)-4/IL-13, key and central drivers of type 2 inflammation in multiple diseases. In phase 3 QUEST (NCT02414854), add-on dupilumab...
6.
Rabe K, FitzGerald J, Bateman E, Castro M, Pavord I, Maspero J, et al.
J Allergy Clin Immunol Pract
. 2022 Aug;
10(11):2916-2924.e4.
PMID: 36028446
Background: The Global Initiative for Asthma report recommends consideration of add-on biologics for patients with type 2 inflammation (blood eosinophils ≥150 cells/μL, fractional exhaled nitric oxide [Feno] ≥20 parts per...
7.
Papi A, Corren J, Castro M, Domingo C, Rogers L, Chapman K, et al.
Allergy
. 2022 Jul;
78(1):233-243.
PMID: 35899469
Background: Severe asthma exacerbations increase the risk of accelerated lung function decline. This analysis examined the effect of dupilumab on forced expiratory volume in 1 s (FEV ) in patients...
8.
Hanania N, Maspero J, Halpin D, Jackson D, Panettieri R, Castro M, et al.
J Asthma Allergy
. 2022 Jul;
15:851-854.
PMID: 35789920
No abstract available.
9.
Wechsler M, Klion A, Paggiaro P, Nair P, Staumont-Salle D, Radwan A, et al.
J Allergy Clin Immunol Pract
. 2022 May;
10(10):2695-2709.
PMID: 35636689
Background: Transient increases in blood eosinophil counts have been observed in dupilumab clinical trials. Objective: To assess eosinophil counts and eosinophilia-related treatment-emergent adverse events (TEAEs) across 11 dupilumab clinical trials,...
10.
Rabe K, Pavord I, Castro M, Wechsler M, Daizadeh N, Kapoor U, et al.
Eur Respir J
. 2022 Apr;
59(6).
PMID: 35487538
No abstract available.